Dergiler / Turkish Journal of Veterinary and Animal Sciences / 2020 / Cilt: 44 - Sayı: 3

Humoral immunity provided by a novel infectious bronchitis vaccine supplemented by bacterium-like particles BLPs

Sayfa
534–541
Yayın Tarihi
2020-06-01
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

In conclusion, BLPs could be a desirable adjuvant for IBV vaccines to increase immunity in chickens.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Infectious bronchitis IB is a notable disease of poultry flocks that results in economic loss.
📊
Temel Bulgular & Veri:As a consequence of the presence of various IB virus IBV serotypes, control strategies, such as vaccination, should be replaced by provide broad protective immunity against the disease to date.
💡
Sonuç & Katkı:In conclusion, BLPs could be a desirable adjuvant for IBV vaccines to increase immunity in chickens.
🔬Tür:Araştırma Makalesi
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Bacterium like particles · IgG · adjuvant

Abstract

Infectious bronchitis IB is a notable disease of poultry flocks that results in economic loss. As a consequence of the presence of various IB virus IBV serotypes, control strategies, such as vaccination, should be replaced by provide broad protective immunity against the disease to date. Gram-positive enhancer matrix particles, or so-called bacterium like particles BLPs , obtained from the bacterium Lactococcus lactis L. lactis , have demonstrated an adjuvancy effect by providing demanding mucosal and humoral immune responses, as well as a protective cellular immunity whenever delivered admixed with a vaccine via intranasal or intraocular administration. In this study, for the first time, attempts were made to investigate the impact of an IBV vaccine supplemented by various doses of BLPs on induced levels of humoral immunity against IB. For this purpose, increasing doses of derived BLPs 0, 0.15, 0.3, and 0.6 mg dry weight per bird were admixed with IBV live attenuated H120 serotype vaccine, and were delivered via ocular administration to 4 equal groups of 10 specific pathogen-free SPF chickens in 4 groups: control, BLP1, BLP2, and BLP3, respectively. In addition, 10 SPF chickens that were not immunized comprised the Unvaccinated group. Blood was collected from 5 members of each group weekly for 35 days. Levels of IgG antibodies in the sera were then assayed using ELISA. Weight gain and the feed conversion ratio of each group were also recorded weekly. Finally, 3 birds from each group were necropsied to evaluate probable lesions. The best results were obtained in the BLP1 group, with IBV vaccination at a low dose of admixed BLPs boosted immediate anti-IBV humoral responses; however, the results were not significantly different from those of the Control group, but were still feasible enough for application in the field. In conclusion, BLPs could be a desirable adjuvant for IBV vaccines to increase immunity in chickens.

🔖

Bu Makaleye Atıf Yap

TOHIDI, E., GHANIEI, A., FARZIN, H., HAGHPARAST, A. (2020). Humoral immunity provided by a novel infectious bronchitis vaccine supplemented by bacterium-like particles BLPs. Turkish Journal of Veterinary and Animal Sciences, Cilt: 44 - Sayı: 3, 534–541. https://ajindex.com/articles/114944

Kaynakça (12)

  1. Orr-Burks N, Gulley SL, Toro H, van Ginkel FW. Immunoglobulin A as an early humoral responder after mucosal avian coronavirus vaccination. Avian Diseases 2014
  2. 58 (2): 279-286. doi: 10.1637/10740-120313-Reg.1 2. Jordan B. Vaccination against infectious bronchitis virus: a continuous challenge. Veterinary Microbiology 2017
  3. doi: 10.1016/j.vetmic.2017.01.002 3. Sjaak de Wit JJ, Cook JK, van der Heijden HM. Infectious bronchitis virus variants: A review of the history, current situation and control measures. Avian Pathology 2011
  4. 40 (3): 323-335. doi: 10.1080/03079457.2011.566260 4. Jackwood MW, Jordan BJ, Roh HJ, Hilt DA, Williams SM. Evaluating protection against infectious bronchitis virus by clinical signs, ciliostasis, challenge virus detection, and histopathology. Avian Diseases 2015
  5. 59 (3): 368-374. doi: 10.1637/11026-012415-reg.1 5. Bande F, Arshad SS, Bejo MH, Moeini H, Omar AR. Progress and challenges toward the development of vaccines against avian infectious bronchitis. Journal of Immunology Research 2015
  6. 424860. doi: 10.1155/2015/424860 6. Cook JK, Jackwood M, Jones RC. The long view: 40 years of infectious bronchitis research. Avian Pathology 2012
  7. 41 (3): 239-250. doi: 10.1080/03079457.2012.680432 7. Feng K, Xue Y, Wang J, Chen W, Chen F et al. Development and efficacy of a novel live-attenuated QX-like nephropathogenic infectious bronchitis virus vaccine in China. Vaccine 2015
  8. 33 (9): 1113-1120. doi: 10.1016/j.vaccine.2015.01.036 8. Zhao Y, Cheng JL, Liu XY, Zhao J, Hu YX et al. Safety and efficacy of an attenuated Chinese QX-like infectious bronchitis virus strain as a candidate vaccine. Veterinary Microbiology 2015
  9. doi: 10.1016/j.vetmic.2015.07.036 9. Yan S, Zhao J, Xie D, Huang X, Cheng J et al. Attenuation, safety, and efficacy of a QX-like infectious bronchitis virus serotype vaccine. Vaccine 2018
  10. 36 (14): 1880-1886. doi: 10.1016/j.vaccine.2018.02.053 10. Li J, Helal ZH, Karch CP, Mishra N, Girshick T et al. A selfadjuvanted nanoparticle based vaccine against infectious bronchitis virus. PLoS One 2018
  11. 13 (9): 1-17. doi: 10.1371/ journal.pone.0203771 11. Wang D, Lu J, Yu J, Hou H, Leenhouts K et al. A novel PspA protein vaccine intranasal delivered by bacterium-like particles provides broad protection against pneumococcal pneumonia in mice. Immunology Investigation 2018
  12. 47 (4): 403-415. doi: 10.1080/08820139.2018.1439505 12. Lu J, Hou H, Wang D, Leenhouts K, Roosmalen MLV et al. Systemic and mucos